anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
SAINTs program will follow a semi-structured, block randomized control design along with a multi-method process evaluation to identify the extent to which the program was delivered as planned and if it led to the adoption of preventative measures. RCT measures will consist of pre/post survey data (at 6 months, 12 months and 24 months) hosted through REDCap and available via link. Additional secondary, de-identified data in aggregate (e.g. # of patient falls, # of worker compensation claims) will supplement survey data. Process evaluation will consist of implementation logs and interviews with key players (safety and quality officers, front-line peer leaders). The semi-structured design allows for customization among different rural healthcare sites that will have unique resources and needs, therefore requiring unique, tailored solutions. The combination of qualitative and quantitative. The SAINTS program will be implemented in four stages. 1) involvement of patient and worker safety stakeholders (e.g., Employee Health and Safety Officer, Quality Director, unit medical directors), 2) use of Social Network Analysis (SNA) to identify peer-recognized safety leaders; 3) training modules to stakeholders on safety leadership, and 4)in implementation of QI cycles to address barriers to safe patient handling and mobility (SPHM).
A method includes receiving location data of a monitoring device when carried by a user and receiving motion data of the monitoring device. The motion data is associated with a time of occurrence and the location data. The method includes processing the received motion data to identify a group of the motion data having a substantially common characteristic and processing the location data for the group of the motion data. The group of motion data by way of processing the location data provides an activity identifier. The motion data includes metric data that identifies characteristics of the motion data. The method includes transferring the activity identifier and the characteristics of the motion data to a screen of a device for display. The activity identifier being a graphical user interface that receives an input for rendering more or less of the characteristics of the motion data.
The present invention involves a method for therapeutic administration of retinoid to an animal. This method, in a preferred embodiment, comprises the basic steps of: preparing liposomes comprising phospholipid and retinoid; and parenterally administering a quantity of the resultant liposomes to the animal, said quantity containing a therapeutically effective amount of the retinoid. The animal being administered the liposomes may bear a tumor impeded by retinoids and the administering step serve to impede growth of said tumor. The most preferred retinoid is all-trans retinoic acid although other retinoids may prove useful. In certain cases, the retinoid may be retinol, particularly all trans-retinol. The phospholipids of the present invention may be one or more of phosphatidylcholine, phosphatidylserine, phosphatidylglycerol, sphingomyelin and phosphatidic acid. These phospholipids, their derivatives and those of analogous structure and hydropathic properties may be used to prepare the liposome-encapsulated retinoids of the present invention as would be apparent to one skilled in the relevant arts upon examination of the present descriptions. The phospholipids of these retinoid-containing liposomes, in a preferred embodiment, comprise dimyristoylphosphatidylcholine and dimyristoylphosphatidylglycerol, still more preferably in about a 7:3 ratio.
The present invention discloses a safe dose of neuregulin applied to people. After 2.99-35.83U / kg (protein / body weight) of neuregulin is intravenously injected into healthy people one time, negative reactions or ECG (electrocardiogram) changes of some people are found, the negative reactions all disappear eight hours after, and the electrocardiogram also returns to normal 7 days after. In all research objects, heart function and breathing are always normal. An attempt is further made to inject 2.99-17.92U / kg of neuregulint into healthy people once in one day for continuous five days, the negative reactions or ECG (electrocardiogram) changes of some people are also found, and the protein dose is higher, the frequency of abnormal electrocardiogram is higher. But the negative reactions quickly disappear, and the electrocardiogram also returns to normal 7 days after the last injection. According to results of clinical trials, 2.99-35.83U / kg of neuregulin can be used as a safe dose for human body.
PURPOSE:To obtain a skin cleansing and wiping material in the title which has a large wiping effect and to eliminate the need of another applying operation at the time of use by impregnating a hydrolysis sheet containing eucalyptic pulp with an oil component. CONSTITUTION:Eucalyptic pulp is contained as pulp for forming a hydrolysis sheet. The eucalyptic pulp is an aggregate of vegetable fibers taken out from an eucalyptus which is an evergreen tall tree native to Australia. The eucalyptic pulp is favorably contained in the hydrolysis sheet by 10-80%. In case of less than 10%, the effect is not enough, and in case of more than 80%, the sheet force is lower, which causes a problem in use. The weighing capacity of the hydrolysis sheet is favorably 10-30g/m<2>, and may be subjected to embossing finish. As an oil component impregnated in the hydrolysis sheet, cited are vegetable oil, animal oil, synthetic oil, silicone oil and so on.
A too-high gestational weight gain, in combination with steadily increasing obesity rates among women of reproductive age, represents an enormous obstetrical problem, as obesity and high gestational weight gain are associated with enhanced fetal growth, low vital parameters, and increased cesarean section rates. This medical record-based study investigates the association patterns between too-low as well as too-high gestational weight gain, according to the 2009 Institute of Medicine (IOM) guidelines, and fetal growth, as well as birth mode and pregnancy outcome. The data of 11,755 singleton births that had taken place between 2010 and 2020 at the Public Clinic Donaustadt in Vienna, Austria, were analyzed. Birth weight, birth length, head circumference, APGAR scores, and pH values of the arterial umbilical cord blood described fetal growth as well as the vital parameters after birth. Gestational weight gain was classified as too low, recommended, or too high according to the different weight status categories of the IOM guidelines. Birth weight, birth length, and head circumference of the newborn were significantly increased (p < 0.001) among underweight, normal-weight, and overweight women who gained more weight than recommended. Among obese women, only birthweight was significantly (p < 0.001) higher among women who gained more weight than recommended. Furthermore, a too-high gestational weight gain was significantly associated with an increased risk of macrosomia and emergency cesarean sections among underweight, normal-weight, and overweight women, but not among obese ones. Obese and morbidly obese women experiencing excessive gestational weight gain showed no significantly increased risk of macrosomia or emergency cesarean section. However, among obese mothers, a too-low gestational weight gain reduced the risk of emergency cesarean sections significantly (p = 0.010). Consequently, the IOM recommendations for gestational weight gain fit only partly for pregnant women in Austria. In the case of obese and morbidly obese women, new guidelines for optimal pregnancy weight gain should be considered.
CASE: Spinal deformity associated with Guillain-Barre syndrome (GBS) is not commonly reported. We present a 6-year-old girl who developed kyphoscoliosis after being diagnosed GBS. She had extensive motor deficits requiring 2 hospitalizations and treatment with IV immunoglobulin therapy. Five months after diagnosis, she presented to our clinic with a 15° coronal scoliosis and a 65° thoracic kyphosis. At 6-month follow-up, kyphosis progressed to 77° with no significant change in the coronal curve. At 1 year, sagittal alignment was within normal limits and the coronal curve had completely resolved.
CONCLUSION: Spinal deformity in GBS can resolve spontaneously.
Granular myringitis is a chronic inflammatory condition of the tympanic membrane that does not involve the middle ear. Various treatment modalities have been proposed for the treatment of granular myringitis, but there is no standard treatment regime. A 60-year-old woman had left persistent ear discharge for 4 months. Examination revealed diffuse granulation tissue, forming a pseudomembrane at the medial aspect of the ear canal and obstructing the tympanic membrane. An audiogram revealed mild-to-moderate left-sided conductive hearing loss. She was treated with multiple courses of ear drop antibiotics but had no improvement. The decision for surgical intervention was driven by the presence of a grade IV medial meatal stenosis, the potential risks associated with prolonged medical management, the distressing impact on the patient's life, and a shared decision-making process. A combined transcanal and postauricular endoscopic approach whereby excision of the granulation tissue, canalplasty, and myringoplasty were performed. She exhibited complete symptom resolution and reported an improved quality of life. This approach yielded successful symptom resolution, highlighting its potential in managing refractory chronic granular myringitis. We aimed to carefully weigh the risks of surgery against its potential benefits in a refractory chronic case, acknowledging the inherent risks and disadvantages of surgical interventions. Further studies are warranted to evaluate the long-term outcomes and benefits of this approach.
PURPOSE: A fluid-jet pen for preparing a bioactive agent-containing emulsion for delivery to a biological system by jetting a bioactive agent and a releasing agent from the fluid-jet pen into a second fluid medium is provided. It allows on-site production if needed, minimizes requirements for long shelf life, uses a small amount of surfactants, thereby reducing side effects related with surfactants, increasing bioavailability and reducing toxicity. CONSTITUTION: With a fluid-jet pen, a bioactive agent-containing emulsion is prepared by the step of jetting (a) a bioactive agent and (b) a releasing agent from a fluid-jet pen into a second fluid medium, wherein the fluid-jet pen is disposed to jet the bioactive agent and releasing agent, thereby associating the bioactive agent and releasing agent. The releasing agent is a first fluid medium, the bioactive agent and releasing agent are jetted to form the bioactive agent-containing emulsion, the second fluid comprises a continuous phase of the emulsion. A microemulsion containing a surfactant in which 0.1 to 10% by weight of the emulsion is present is prepared with the fluid-jet pen. A bioactive agent release system contains packaging a fluid-jet pen containing the bioactive agent and releasing agent in a sterilized environment and providing sterilized associates.
Systems and methods of generating and applying a synthetic neuromodulatory signal are described. A subject may be put under a particular condition that causes an effect in the subject. While the subject is under the condition, a recording of neurogram signals derived from the condition can be made from the subject. For example, neuronal signals traveling on the vagus nerve of the subject may be monitored and recorded. The neurogram may then be used to create a synthetic neuromodulatory signal that can be administered to a user. When the synthetic neuromodulatory signal is administered to the user, the user may experience the same effect as the subject that had been placed in the condition, even though the user was never put under the same condition.
It is intended to provide a morphinan derivative represented by the following general formula (I): (I) wherein R1 represents methyl, cyclopropylmethyl, etc.; R2 and R3 represent each hydroxy, methoxy, acetoxy, etc.; Y and Z represent each a valence bond, -(C=O)-, etc.; X represents a C2-5 carbon chain constituting a part of the cyclic structure (wherein one of the carbon atoms may be substituted by oxygen, sulfur or nitrogen); (R4)k represents an optionally substituted fused benzene ring, carbonyl, etc.; R9 represents hydrogen, etc.; R10 and R11 may be bonded together to form -O-; and R6 represents hydrogen, etc.; a pharmacologically acceptable acid addition salt thereof, a remedy or a preventive for urinary frequency or urinary incontinence containing the above derivative or its pharmacologically acceptable acid addition salt as the active ingredient; a method for treating or preventing the above diseases; and utilization for these diseases. The above-described compound is useful as a novel remedy or preventive for urinary frequency or urinary incontinence showing an isolated side effect. Moreover, it is useful in a method for treating or preventing the above diseases and utilization for these diseases.
Regulating the gut microbiota alleviates hepatic encephalopathy (HE). Whether it is imperative to withhold treatment for microbial imbalance after liver functional recovery remains unclear. The aim of this work was to elucidate the alterations in cognitive behavior, liver function, synaptic transmission, and brain metabolites in acute liver failure (ALF) mice before and after hepatic function recovery. Towards this end, thioacetamide was injected intraperitoneally to establish an ALF mouse model, which induced HE. Hierarchical clustering analysis indicated that while the liver functions normalized, cognitive dysfunction and intestinal dysbacteriosis occurred in the ALF mice 14 days after thioacetamide injection. In addition, fecal microbiota transplantation from the ALF mice with liver function recovery induced liver injury and cognitive impairment. Alterations in synaptic transmission were found in the ALF mice with liver function improvement, and the correlations between the gut bacteria and synaptic transmission in the cortex were significant. Finally, apparent alterations in the brain metabolic profiles of the ALF mice were detected after liver function improvement by performing 1H nuclear magnetic resonance spectroscopy, suggesting a risk of HE. These results showed that intestinal dysbacteriosis in ALF mice with liver function recovery is sufficient to induce liver injury and cognitive impairment. This indicates that continuous care may be necessary for monitoring microbial imbalance even in patients with ALF-induced HE whose liver function has recovered significantly.
A serum ferritin level <15 to 20 μg/L historically identified patients who had absent bone marrow iron stores, but serum ferritin levels are distorted by the systemic inflammatory states seen in patients with chronic kidney disease or heart failure. As a result, nearly 25 years ago, the diagnostic ferritin threshold was increased 5- to 20-fold in patients with chronic kidney disease (ie, iron deficiency was identified if the serum ferritin level was <100 μg/L, regardless of transferrin saturation [TSAT], or 100 to 299 μg/L if TSAT was <20%). This guidance was motivated not by the findings of studies of total body or tissue iron depletion, but by a desire to encourage the use of iron supplements to potentiate the response to erythropoiesis-stimulating agents in patients with renal anemia. However, in patients with heart failure, this definition does not reliably identify patients with an absolute or functional iron-deficiency state, and it includes individuals with TSATs (≥20%) and serum ferritin levels in the normal range (20-100 mg/L) who are not iron deficient, have an excellent prognosis, and do not respond favorably to iron therapy. Furthermore, serum ferritin levels may be distorted by the use of both neprilysin and sodium-glucose cotransporter 2 inhibitors, both of which may act to mobilize endogenous iron stores. The most evidence-based and trial-tested definition of iron deficiency is the presence of hypoferremia, as reflected by as a TSAT <20%. These hypoferremic patients are generally iron deficient on bone marrow examination, and after intravenous iron therapy, they exhibit an improvement in exercise tolerance and functional capacity (when meaningfully impaired) and show the most marked reduction (ie, 20%-30%) in the risk of cardiovascular death or total heart failure hospitalizations. Therefore, we propose that the current ferritin-driven definition of iron deficiency in heart failure should be abandoned and that a definition based on hypoferremia (TSAT <20%) should be adopted.
Subject is currently exhibiting fever, or one or more symptoms associated with COVID-19 or influenza (such as, but not limited to, chills, cough, shortness of breath or difficulty breathing, fatigue, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting or diarrhea) and must present within 6 days of symptom onset. Subject must still be exhibiting symptoms on the day of sample collection.
The present invention relates to cancer markers and methods of detecting cancer markers in a sample. The sample may be peripheral blood. Cancer markers are most commonly mutated or abnormal DNA sequences associated with metastatic cancer. Markers may be detected using PCR, microarrays, or other nucleic acid or peptide-based assays. These methods may be used for a variety of diagnostic purposes, including initial, early-stage or later diagnosis of cancer, particularly metastatic cancer and monitoring of cancer or treatment progression. The cancer markers may also be used to create a cancer marker profile. Treatment may be directed based on this profile. Additionally, methods using blood may provide a cancer marker profile of mutations or abnormalities found in at least one of several tumors in the body, instead of merely one tumor. The invention also include kits, such as primer kits, and microarrays for use in performing the various methods.
Myogenic transcription factors with a basic helix-loop-helix (bHLH) such as MYOD, myogenin, MRF4, and MYF5 contribute to muscle differentiation and regulation. The MYF5 gene located on chromosome 12 encodes for myogenic factor 5 (MYF5), which has a role in skeletal and extraocular muscle development and rib formation. Variants in MYF5 were found to cause external ophthalmoplegia with rib and vertebral anomalies (EORVA), a rare recessive condition. To date, three homozygous variants in MYF5 have been reported to cause EORVA in six members of four unrelated families. Here, we present a novel homozygous MYF5 frameshift variant, c.596dupA p. (Asn199Lysfs*49), causing premature protein termination and presenting with external ophthalmoplegia, ptosis, and scoliosis in three siblings from a consanguineous family of Pakistani origin. With four MYF5 variants now discovered, genetic testing and paediatric assessment for extra-ocular features should be considered in all cases of congenital ophthalmoplegia.
Once a plastic catheter is placed, within 24 hours of placement, the catheter will be connected to a small pump at the bedside, and the convection-enhanced delivery of the Topotecan will begin. The Topotecan will be infused for 4 to 5 days after which time the catheters will simply be pulled out. Patients will be monitored with blood tests and MRI scans during the treatment and at different time periods during the following months.
SDD for ICD is a prospective, randomized, multi-center study designed to show that SDD is safe in a defined patient population receiving an ICD implant and that this approach can be more cost effective for the hospital than the current NDD approach. Safety is to be demonstrated by showing that postoperative complications do not occur at a higher rate in the SDD group of patients when compared to the NDD group. Cost effectiveness is to be demonstrated by comparing health care utilization between the SDD and NDD groups for the first week post implantation. Patients who were implanted with a St. Jude Medical single or dual chamber ICD for primary prevention and who met all inclusion and exclusion criteria may be enrolled in the study. Patients areconsidered enrolled at the point of randomization.

Randomization is assigned in a 1:1 ratio between the NDD group and the SDD group. Patients will undergo study evaluations after implant, pre-discharge, 1-week and 6 months post implant.
When the drain produces less than 100 mL over 24 hours, the self-suction bulb is removed and the drain is shortened and drained into a colostomy bag placed around the site of drain insertion. A request is filed with the community nursing system to have a visiting nurse to pull out the drain 1-2 cm per day.
Case presentation: A 25-year-old male patient presented to the emergency department with generalized peritonitis caused by a perforated jejunal mass. The patient underwent an emergency exploratory laparotomy. There was 800 ml of thin pus in the peritoneal cavity and 5 cm by 6 cm perforated mass over the jejunum, 30cm from the ligament of the treitz, which extends to the mesentery. Palpable jejunal mesenteric lymphadenopathies were found. There were palpable intraluminal polyps with an inverted serosal surface for some of them, which were identified as 10cm proximal and 20cm distal to the mass. The pus was sucked out, and the mass was resected with its mesenteric lymph nodes and segments containing polyps, a total of 40cm of jejunum. Subsequently, end-to-end hand-sewn anastomosis was performed, and the abdomen was closed. The histopathology report showed poorly differentiated adenocarcinoma, stage IIIC (PT3, PN2), and Peutz-Jeghers polyps, suggesting Peutz-Jeghers syndrome. Lympho-vascular invasion was also noted. The tumor has affected seven of the 12 lymph nodes that have been identified. After 6weeks of uneventful follow-up at the surgical referral clinic, the patient was referred to the oncology department for adjuvant chemotherapy.
A vector for use in the nucleic acid protection from enzymes through, after conglomeratization of a nucleic acid, arranging a vector containing a cationic polymer around the agglomerates. In particular, a vector comprising a polymer having a branched chain. Preferably, a 3, 4 or 6-branched chain is bonded to a benzene ring. It is preferred that the number of branched chains be large. The branched chain preferably consists of a vinyl type acrylic polymer. This vector can be synthesized by reacting a dithiocarbamate compound with an acrylamide monomer for branched chain.
PROBLEM TO BE SOLVED: To provide a diagnostic drug and a therapeutic drug, for an autoimmune disease, in which pyruvate carboxylase is used as a target. SOLUTION: The diagnostic drug, for the autoimmune disease, which contains the protein-amount measuring reagent of the pyruvate carboxylase is provided. The diagnostic drug, for the autoimmune disease, which contains the expression- amount measuring reagent of a gene used to code the pyruvate carboxylase is provided. A nonhuman autoimmune-disease-model animal which uses the diagnostic drug is provided. A diagnostic method for the disease state of its control animal is provided. The gene therapeutic drug and/or a preventive drug, for the autoimmune disease, in which the gene used to code the pyruvate carboxylase as an effective component are provided.  In a screening method for the gene expression promotion substance of the pyruvate carboxylase, a plasmid in which the expression adjusting region of the gene used to code the pyruvate carboxylase is connected to a reporter gene is introduced into a cell, a transformed cell is created, a specimen is added to the transformed cell, and whether the specimen increases the expression amount of the reproter gene or not is measured and evaluated.
Tricuspid valve replacement in patients for the surgical management of tricuspid valve disease, including tricuspid valve disease secondary to congenital heart disease. Enrollment will include up to 60 adults subjects and up to 18 pediatric subjects.